Heron Therapeutics/HRTX

$2.71

4.23%
-
1D1W1MYTD1YMAX

About Heron Therapeutics

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF, HTX-019, and HTX-034. HTX- ZYNRELEF is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting in adults. HTX-034 is a product candidate for postoperative pain management.

Ticker

HRTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Craig Collard

Employees

203

Headquarters

San diego, United States

HRTX Metrics

BasicAdvanced
$390.19M
Market cap
-
P/E ratio
-$0.97
EPS
1.67
Beta
-
Dividend rate

What the Analysts think about HRTX

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
146.13% upside
High $9.00
Low $4.00
$2.71
Current price
$6.67
Average price target

HRTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-79.61% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$31.4M
-0.95%
Net income
$-25M
-40.48%
Profit margin
-79.61%
-39.91%

HRTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 41.88%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.17
-$0.27
-$0.35
-$0.17
-
Expected
-$0.29
-$0.20
-$0.23
-$0.29
-$0.16
Surprise
-40.35%
33%
49.96%
-41.88%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Heron Therapeutics stock

Buy or sell Heron Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing